Abstract
Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have